Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten
- Accretive Commercialization Services Agreement covering six mature assets across critical care, cardiovascular, and metabolic disease leveraging Everest's existing commercial organization - Exclusive Greater China license to develop and...
Hasten Accelerates Asia-Pacific Expansion with Successful MAT Transfers of 11 Products
SHANGHAI, June 16, 2025 /PRNewswire/ -- Hasten Biopharmaceutical Co., Ltd. ("Hasten") announced today the completion of Market Authorization Transfers (MAT) for 11 major pharmaceutical products across several key Asia-Pacific markets, including...